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Background: Dual antiplatelet therapy is the cornerstone in the management of acute cor-
onary syndromes (ACS) and prevention of stent thrombosis (ST). Genetic polymorphisms in
CYP2C19 gene involved in hepatic activation of clopidogrel leads to clopidogrel non-
responsiveness and may influence clinical outcomes. These polymorphisms in CYP2C19
gene and their impact on clinical outcome in coronary artery disease (CAD) have not been
studied in Indian population.
Methods:We studied 110 consecutive patients (mean age 55.7  10.7 years; 90%male) taking
clopidogrel with angiographically proven CAD for various genetic polymorphisms in
CYP2C19 gene. Relationship between loss of function mutation and clinical presentation
with recurrent ACS including ST was analyzed.
Results: Out of 110 patients, 26 (23.64%) had normal genotype, 52 (47.23%) had loss of
function mutation *2 and 39 (35.45%) had a gain of function mutation *17, 7 (6.36%) patients
were undefined metabolizers (*2/*17) which were excluded from analyses. Final analyses
included 103 patients, with 45 (40.90%) having loss of function. Overall 51 patients had ACS,
with 27 developing recurrence while on clopidogrel. The prevalence of loss of function
mutation was no different between the group with recurrences and those without re-
currences (55.6% vs. 50%, p ¼ 0.7). Two patients developed ST while on clopidogrel; both
had loss of function mutation.
Conclusion: CYP2C19 gene polymorphisms are common in Indian population. Loss of
function mutation status did not affect the clinical outcomes. A larger study also consid-
ering P2Y12 receptor polymorphisms together with platelet activity testing, may be
required to establish the role of CYP2C19 gene polymorphisms in clinical practice.
Copyright ª 2013, Cardiological Society of India. All rights reserved.; fax: þ91 11 26588663, þ91 11 26588641.
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i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 1 6e2 4 171. Introduction those taking omeprazole were excluded. The study isDual antiplatelet therapy with aspirin and clopidogrel is the
cornerstone in the management of STEMI,1 acute coronary
syndromes (UA/NSTEMI),2 prevention of stent thrombosis (ST)
in patients undergoing percutaneous coronary intervention
(PCI)3 and patients with high risk chronic stable angina.4 In
spite of significant benefits of dual antiplatelet treatment
proven in various trials, adverse ischemic events, including
stent thrombosis, do occur and continue to haunt clinicians
worldwide. It is well established that the antiplatelet response
to clopidogrel shows tremendous individual variation in the
level of platelet inhibition achieved.5,6 Patients displaying lit-
tle attenuation (<30%) of platelet reactivity under clopidogrel
therapy are recognized as low or non-responders, while those
with <10% attenuation are termed as clopidogrel resistant.7,8
Clopidogrel is a pro-drug that requires hepatic bioactivation
involving 2steps, which are regulated by cytochromes (CYP).9
The genes encoding the enzymes are characterized by
several polymorphisms, some of which are able to modify the
activity of proteins, reducing the concentration of active
metabolite.10,11 Carriers of at least one CYP2C19 reduced-
function allele had a relative reduction of 32.4% in plasma
exposure to the active metabolite as compared to non-
carriers, whereas the carriers of other CYP reduced-function
alleles did not have significant differences in platelet inhibi-
tion as compared to non-carriers.12
Several studies have associated these gene polymorphisms
with inadequate platelet inhibition resulting in adverse clin-
ical outcomes, including recurrent ischemic cardiovascular
events, stent thrombosis (ST) and peri-procedural myocardial
infarction.12e17 Based on these studies, ACC (American
College of Cardiology) has issued an advisory stating that, “
genetic testing to determine if a patient is predisposed to poor
clopidogrel metabolism (“poor metabolizers”) may be consid-
ered before starting clopidogrel therapy in patients believed to
be at moderate or high risk for poor outcomes”.18
The frequency of CYP2C19 polymorphism shows varia-
tions among different ethnic groups, which translates into
significantly variable metabolic phenotypes across the pop-
ulations. CYPC19 polymorphisms and their impact on clinical
outcomes in CAD patients have not been studied in Indian
population. We conducted this study to identify and describe
the distribution of genetic polymorphisms in CYP2C19 gene in
Indian patients and study relationship between loss of func-
tion mutation and presentation with recurrent ACS including
ST while taking adequate dose of clopidogrel.2. Material and methods
We conducted a prospective cohort study in a tertiary hospital
in north India. We studied 110 patients of angiographically
proven CAD taking clopidogrel. Patients with history of major
bleeding, recent history of stroke or transient ischemic attack
(TIA), clopidogrel/aspirin sensitivity, renal dysfunction, he-
patic dysfunction, malignancy, patients having non-coronary
indication for clopidogrel (e.g. renal/carotid stenting), patients
on other P2Y12 antagonists within 4 weeks of inclusion andapproved by Institute’s ethics committee.
Written and informed consent was taken from all eligible
patients prior to inclusion into the study. All patients were
questioned regarding any of the above mentioned exclusion
criteria, coronary risk factors, history of medications they
have been taking, past history of STEMI, ACS and percuta-
neous coronary interventions. The patients were divided into
2 groups.2.1. Recurrent ACS group
Patients who developed an episode of stent thrombosis or
acute coronary syndrome while they were taking adequate
dose of dual antiplatelet agents.2.2. No recurrence group
All other patients on clopidogrel initiated for the first event or
prior to PCI without clinical recurrence of ACS.
The baseline demographic and coronary details were
recorded in a standard proforma. Standard definitions of ACS
as defined by ACC guidelines were used in the study. The
patients were managed as per current guideline by their
physicians. A blood sample (10ml) was collected in EDTA anti-
coagulated vacutainer and stored for genetic analysis of
CYP2C19 polymorphisms at 80 C.2.3. Method of genetic testing
The method followed was based on the Sequenom MassAR-
RAY platform (Sequenom Inc, San Diego, CA). The assay was
based on primer extension and offers two levels of specificity.
First, a locus-specific amplification PCR reaction took place,
followed by a locus-specific primer extension reaction, in
which an oligonucleotide primer annealed immediately up-
stream of the polymorphic site being genotyped. In the iPLEX
assay, the primer and amplified target DNA were incubated
with mass-modified dideoxynucleotide terminators. The
primer extension was made according to the sequence of the
variant site, and was a single complementary mass-modified
base. Through the use of MALDIeTOF mass spectrometry
(Dynamo, Thermo Bioanalysis, Santa Fe, NM) the mass of the
extended primer was determined. The primer’s mass indi-
cated the sequence and, therefore, the alleles present at the
polymorphic site of interest. Sequenom supplied software
(TYPER) that automatically translated the mass of the
observed primers into a genotype for each reaction.
The assay reported the alleles as *1, *2, *3, *4, *5 and *17 and
reported genotypes as normal extensive metabolizers (*1/*1),
poormetabolizers (*2e*5/*2e*5), intermediatemetabolizers (*1/
*2e*5), undefined phenotype (*17/*2e*5) and ultra-rapid
metabolizers (*17/*17 and *1/*17). Based on this two groups
were made, one with loss of function allele (homozygous or
heterozygous for *2e*5 allele,which includes *2e5/*2e5 and *1/
*2e5) and another without loss of function allele (not having
any *2e*5 allele, which included *1/*1, *1/*17, and *17/*17). The
allele *17/*2e5was labelled as undefined phenotype. There are
various publications based on the currently used assay.19e22
Table 1 e Demographic features of the study population.
Characteristics Total
n ¼ 110
n%
Age (years) 55.7  10.7
Sex Male 90 81.8%
Coronary Risk
factors
Hypertension 68 61.8%
Diabetes 39 35.5%
Dyslipidemia 36 32.7%
Smoker 29 26.4%
Tobacco chewer 30 27.3%
Obese 27 24.5
Positive family history 22 20%
Medical
treatment
Aspirin 110 100%
Clopidogrel 110 100%
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The description of genetic polymorphism profile of consecu-
tive Indian patients is reported as a percentage. Continuous
values are expressed as mean  SD. For normally distributed
continuous variables, the Student’s t-test was applied for
comparison between two groups. Pearson’s Chi-square test
was used for evaluating dichotomous variables. Number of
patients with reduced-function mutations in recurrent ACS
versus first time ACS group were compared using Pearson’s
Chi-square test with two tailed significance level. A p value of
<0.05 was considered significant. Analysis was done on SPSS
statistics 17.0 (IBM corp.).
Beta-blocker 110 100%
ACEI/ARB 78 70.9%
Statins 110 100%
Presentation CSA 57 51.8%
STEMI 22 20%
UA/NSTEMI 29 26.4%
Stent thrombosis 2 1.8%
Coronary
angiography
Normal 14 12.7%
SVD 41 37.3%
DVD 30 27.3%
TVD 21 19.1%
LMCA disease 4 3.6%
LV function Normal 64 58.2%
LV dysfunction (LVEF <55%) 46 41.8%
ACEI: Angiotensin converting enzyme inhibitor, ARB: angiotensin
receptor blocker, CSA: chronic stable angina, STEMI: ST elevation
myocardial infarction, NSTEMI: non-ST elevation myocardial
infarction, UA: unstable angina, ACS: acute coronary syndrome;
SVD: single vessel disease, DVD: double vessel disease, TVD: triple
vessel disease, LMCA: left main coronary artery, LV: left ventricle,
LVEF: LV ejection fraction.4. Results
Out of the 125 patientswith diagnosed coronary artery disease
taking clopidogrel, 15 patients were excluded for not giving
consent.
4.1. Characteristics of study population
Baseline characteristics of study population are shown in
Table 1. Majority of 57 (51.8%) patients presented with CSA
(Chronic stable angina), while 22 (20%) and 29 (26.4%) pre-
sented with STEMI or UA/NSTEMI respectively. There were
two instances of ST (1.8%). In all, 53 (48.2%) presented with
acute coronary events, 28 patients of these presented with
recurrence of ACS while taking adequate dose of clopidogrel.
4.2. Genetic analysis
The frequency of CYP2C19 mutant alleles in study population
is shown in Fig. 1a. Genetic analysis revealed presence of loss
of function allele *2 and gain of function allele *17 in the study
population, while there were no *3, *4 or *5 loss of function
alleles. Only one fourth (26 patients) carried the normal wild
type allele *1 at both (homozygous) loci, 52 patients (47.27%)
carried loss of function allele *2 at both (homozygous) or one
(heterozygous) loci, 39 patients (35.46%) carried gain of func-
tion allele *17 at both (homozygous) or one (heterozygous) loci
and 7 patients (6.36%) carried both *2 and *17 mutations.
Twenty-six patients (23.60%) had normal genotype and
were homozygous for the wild allele *1, 16 patients (14.50%)
were homozygous for loss of function allele *2, 7 patients
(6.40%) were homozygous for gain of function allele *17, 29
patients (26.40%) were heterozygous with one loss of function
allele *2 and other normal allele, 25 patients (22.70%) were
heterozygous with one gain of function allele *17 and other
normal allele while 7 patients (6.40%) formed the undefined
group which were heterozygous with both loss of function
allele *2 and gain of function allele *17 (Fig. 1b).
Patients with *2 mutation are either homozygous (*2/*2) or
heterozygous (*1/*2), and are termed as poor metabolizers and
intermediate metabolizers respectively. Patients with *17
mutation are either homozygous (*17/*17) or heterozygous (*1/
*17), both are classified as metabolically ultra-rapid metabo-
lizers. Patients homozygous for normal wild type allele *1 i.e.(*1/*1) are metabolically normal and are extensive normal
metabolizers. The genotype heterozygous for both *2 and *17
mutation (*2/*17) is termed as undefined metabolizer, because
metabolizer status of this genotype is unknown. This group of
undefined metabolizer patients has been uniformly excluded
from analysis in clinical trials. Twenty-six patients (23.60%)
were normal extensive metabolizers, 16 patients (14.50%)
were poor metabolizers, 29 patients (26.40%) were intermedi-
ate metabolizers, 32 patients (29.10%) were ultra-rapid
metabolizers and 7 patients (6.40%) formed the undefined
group (Fig. 1c).
4.3. Distribution of CYP2C19 genotypes within ACS and
CSA group
Distribution of CYP2C19 genotypes individually in patients
presenting with CSA and ACS is shown in Table 2. More
number of patients in ACS group had loss of function muta-
tion (27/53, 50.94%) as compared to patients in chronic stable
angina group (18/57, 31.58%). Numerically more patients in
CSA group had normal CYP2C19 phenotype as compared to
ACS group (18/57, 31.58% versus 8/53, 15.09%). Gain of function
mutation was no different between both groups (16/57 versus
16/53). However these differences were not statistically sig-
nificant (p ¼ 0.079).
Fig. 1 e a e Frequency of CYP2C19 mutant alleles in study population. b e Frequency of clopidogrel genotypes in study
population. c e Frequency of CYP2C19 alleles, according to metabolizer status in the study population. d e Patient groups
according to loss of function versus no loss of function genotype in the study population.
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function genotype
For analysis of loss of function genotype relationship with
coronary events the patients were analyzed in two groups,
one with loss of function and the other without loss of func-
tion allele. Out of 110 patients, 58 (52.70%), 45 (40.90%) and 7
patients (6.40%) were in no loss of function, loss of function
and undefined groups respectively (Fig. 1d). The undefined
group (n ¼ 7) was excluded from the analysis as their metab-
olizer status is unknown and final analysis was done in 103
patients. The undefined metabolizer group with genotype *2/
*17 had 2 males and 5 females, 5 patients presented with CSA
while 2 presented with ACS, only one patient from this group
had recurrent ACS while on clopidogrel.
More patients in loss of function group (n ¼ 27 of 45, 60%)
presented with an acute coronary syndrome (STEMI/NSTEMI/
USA) as compared to 41.4% (n ¼ 24 of 58) patients in no loss of
function group, however this difference didn’t reach statisti-
cal significance (p ¼ 0.061). There were two cases of stent
thrombosis and bothwere in loss of function group. Therewas
no significant difference between both groups in any of the
baseline characteristics (Table 3).Table 2 e Distribution of CYP2C19 genotypes according to the
coronary syndrome including stent thrombosis).
Chroni
angina
Genotypes *1  *1 1
*1  *2 1
*2  *2
*1  *17 1
*17  *17
*2  *17
Status of mutation Normal (*1  *1) 1
Loss of function (*1  *2, *2  *2) 1
Gain of function (*1  *17, *17  *17) 1
Undefined (*2  *17)
# Includes two patients with stent thrombosis.4.5. CYP2C19 loss of function and recurrent coronary
events on clopidogrel within ACS group
Out of total 103 patients (after excluding 7 patients with un-
defined metabolizer status), 51 presented with ACS. Of these
51 patients, 27 patients (52.94%) presented with second or
subsequent (recurrent) episode of acute coronary syndrome
while on adequate dose of clopidogrel, while 24 patients
(47.05%) presented with first episode of acute coronary
syndrome.
Baseline characteristics between recurrent ACS group and
no recurrence group are shown in Table 4. There was no sig-
nificant difference between both groups in terms of age,
gender, coronary risk factors, extent of coronary artery dis-
ease and LV dysfunction. All patients in both groups were
receiving aspirin, clopidogrel, beta-blockers and statins.
Significantly more number of patients 88.9% (24 out of 27) in
recurrent ACS group were receiving ACEI/ARB as compared to
no recurrence (first event of ACS) group 62.5% (15 out of 24),
p ¼ 0.027.
Fifteen patients (55.6%) of recurrent ACS Group had a loss
of function mutation in CYP2C19 (*1/*2 or *2/*2) while 12 pa-
tients (50%) of no recurrence group had loss of functionmode of presentation (chronic stable angina versus acute
c stable
(n ¼ 57)
n% Acute coronary
syndrome (n ¼ 53)#
n% p value
8 31.58 8 15.09
3 22.81 16 30.19
5 8.77 11 20.75
4 24.56 11 20.75
0.101
2 3.51 5 9.43
5 8.77 2 3.77
8 31.58 8 15.09
8 31.58 27 50.94
6 28.07 16 30.19
0.079
5 8.77 2 3.77
Table 3 e Comparison between patient with loss of function and no loss of function mutations.
Characteristics Loss of function mutation
(n ¼ 45)
No loss of function mutation
(n ¼ 58)
Total
n ¼ 103
Total % p value
Age (years) 54.71  10.72 55.34  10.25 55.07  10.41 0.188
Sex Male 41 91.1% 47 81% 88 85.4% 0.150
Female 4 8.9% 11 19% 15 14.6%
Coronary risk factors Hypertension 30 66.7% 32 55.2% 62 60.2% 0.237
Diabetes 16 35.6% 19 32.8% 35 34.0% 0.766
Dyslipidemia 14 31.1% 18 31% 32 31.1% 0.993
Smoking 13 22.4% 15 33.3% 28 27.18% 0.440
Presentation CSA 18 40% 34 58.6% 52 50.5% 0.132
STEMI 12 26.7% 10 17.2% 22 21.4%
USA/NSTEMI 13 28.9% 14 24.1% 27 26.2%
Stent thrombosis 2 4.4% 0 0% 2 1.9%
Presentation (CSA v/s ACS) CSA 18 40% 34 58.6% 52 50.5% 0.061
ACS 27 60% 24 41.4% 51 49.5%
Coronary angiography Normal 5 11.1% 6 10.3% 11 10.7% 0.505
SVD 21 46.7% 18 31% 39 37.9%
DVD 10 22.2% 19 32.8% 29 28.2%
TVD 8 17.8% 12 20.7% 20 19.4%
LMCA disease 1 2.2% 3 5.2% 4 3.9%
Left ventricular dysfunction (LVEF <55%) 16 35.6% 29 50% 45 43.7% 0.143
CSA: chronic stable angina, STEMI: ST elevation myocardial infarction, USA: unstable angina, NSTEMI: non-ST elevation myocardial infarction,
ACS: acute coronary syndrome, SVD: single vessel disease, DVD: double vessel disease, TVD: triple vessel disease, LMCA: left main coronary
artery, LVEF: left ventricular ejection fraction.
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cant (p ¼ 0.692).5. Discussion
Polymorphisms in cytochromes which modify the activity of
hepatic enzymes, leading to reduce concentration of activeTable 4 e Comparison between patients with recurrent ACS on
Characteristic Recurrent ACS
group (n ¼ 27)
Age (years) 56.74  10.39
Sex Male 22 81.5%
Female 5 18.5%
Coronary Risk factors Hypertension 19 70.4%
Diabetes 7 25.9%
Dyslipidemia 8 29.6%
Smoker 12 44.4%
Tobacco chewer 8 29.6%
Obese 8 29.6%
Family history 6 22.2%
Medical treatment Aspirin 27 100%
Clopidogrel 27 100%
Beta blocker 27 100%
ACEI/ARB 24 88.9%
Statins 27 100%
Coronary angiography Normal 1 3.7%
SVD 10 37.0%
DVD 9 33.3%
TVD 6 22.2%
LMCA disease 1 3.7%
LV dysfunction (LVEF <55%) 16 59.3%
ACS: acute coronary syndrome, SVD: single vessel disease, DVD: double
artery, LV: left ventricle, ACEI: angiotensin converting enzyme inhibitor,
Indicated bold p values are significant.metabolite, is one of the key factor involved in clopidogrel
resistance.10,11 Various loss of function alleles of CYP2C19
have been found and studied. The CYP2C19*2 allele is themost
common type among the reduced-function genes and has
been shown as a prime indicator of low response to clopi-
dogrel in many studies.23,24 Recently studies have shown that
CYP2C19*3, *4, *5, *6, *7 and *8 alleles may also affect clopi-
dogrel metabolism in the same way as CYP2C19*2, howeverclopidogrel group versus no recurrence group.
No recurrence
group (n ¼ 24)
Total n ¼ 51 Total % p value
53.38  11.86 55.16  11.124 0.426
23 95.8% 45 88.2% 0.112
1 4.2% 6 11.8%
13 54.2% 32 62.7% 0.232
8 33.3% 15 29.4% 0.562
6 25.0% 14 27.5% 0.137
7 29.2% 19 37.3% 0.260
5 20.8% 13 25.5% 0.472
5 20.8% 13 25.5% 0.472
5 20.8% 11 21.6% 0.904
24 100% 51 100%
24 100% 51 100%
24 100% 51 100%
15 62.5% 39 76.5% 0.027
24 100% 51 100%
2 8.3% 3 5.9% 0.541
13 54.2% 23 45.1%
5 20.8% 14 27.5%
4 4% 10 19.6%
0 0% 1 2.0%
15 62.5% 31 60.8% 0.813
vessel disease, TVD: triple vessel disease, LMCA: left main coronary
ARB: angiotensin receptor blocker, LVEF: LV ejection fraction.
Fig. 2 e Relationship of loss of function mutation with
recurrence of acute coronary events.
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CYP2C19*2 allele.25 An allele CYP2C19*17 is associated with
increased activity and is been found to be having higher
platelet inhibition as compared to the normal.10,11
Even though our results cannot be compared with studies
involving general population, certain inferences can be made.
Our study showed a high prevalence of CYP2C19 poly-
morphism in a specific group of CAD population, than reported
in earlier epidemiological studies conducted in general popu-
lation. The frequency of CYP2C19*2 allele associated with poor
metabolizer type was observed to be 47.23% in CAD patients
which is higher than that in general population as previously
reported by Adithan et al26 in south Indian Tamil population
(37.9%) and by Kavita et al27 in western Indian population
(35.2%).We did not find any loss of function CYP2C19*3 allele in
our study population, which is similar to as observed in
western Indian population.27 However this allele though rare
(2.2%) was detected in Tamilian population.26 Other loss of
function alleles CYP2C19*4 and *5, were not detected in our
study population. These rare alleles have not been previously
studied in Indian population, and probably are very rare like in
other worldwide populations.10 Unlike CYP2C19*2 allele, the
gain of function allele CYP2C19*17 associated with rapid
metabolism has not been adequately studied in Indian popu-
lation. Kavita et al27 and Chan et al28 reported the frequency of
CYP2C19*17 allele to be 18% and 16.5% respectively in the In-
dian population. We observed higher allelic frequency of
CYP2C19*17 at 35.45% in our study population involving CAD
patients. Frequency of CYP2C19 alleles studied in varied pop-
ulations is shown in Table 5. CYP2C19*2 loss of function allele
is very common in Indian population as compared to the otherTable 5 e Reported frequencies of CYP2C19 alleles in varied po
Population *1 allele *2 allele *
African10 68% 15%
American10 69% 12%
European10 63% 15%
South/Central Asian10 62% 35%
South Indian26 NA 37.9%
Western Indian27 NA 35.2%
Indian28 NA 37.5%
Present study 23.64% 47.23%
NA: not analyzed.populations studied worldwide. There is also disparity among
the Indian population in terms of CYP2C19*17 allele, north
Indian population had a higher frequency of this mutation as
compared to south Indian population. This difference is
attributed to different ethnic population with varied genetic
pool among the studied groups.
Various studies andmeta-analyseshave associatedCYP2C19
loss of function mutation with adverse clinical outcomes
including stent thrombosis (ST).12,13 A genetic substudy of
TRITON-TIMI38 trial12 studied thishypothesis inacohortof1477
subjects with ACS, all of whom were on clopidogrel and were
managed invasively with coronary artery stenting. 27.1% of the
patients in this study group had at least one reduced-function
CYP2C19 allele out of either *2, *3, *4, *5, *6, *7, *8, *9, *10, *12, *13
or *14 allele. The primary outcome of composite death from
cardiovascular causes, myocardial infarction, or stroke was
compared between two dichotomous groups, one with loss of
function allele and the other not carrying such a mutation. Pri-
mary outcomewas reached in 12.1% of patients carrying at least
onereduced-functionmutationascomparedto8.0%inthosenot
harboring it, HR for carriers 1.53; 95%CI, 1.07e2.19 (p¼ 0.01). The
secondary outcome of ST was also significantly high in carriers
(2.6%) than non-carriers (0.8%), p ¼ 0.02. Similarly a meta-
analysis of nine studies involving patients predominantly
managed invasively with PCI, showed significantly higher rates
of adverse clinical events (death from cardiovascular cause,
myocardial infarction or stroke), HR 1.55 (95% CI, 1.11e2.27,
p ¼ 0.01) and stent thrombosis, HR 2.67 (95% CI, 1.69e4.22,
p < 0.0001), among carriers of reduced-function clopidogrel
allele.13
In our study we did not found any significant interaction
between the loss of function group (*2/*2, *1/*2) and no loss of
function group (*1/*1, *1/*17, *17/*17) in clinical presentation.
Two of our patients had stent thrombosis while on adequate
dose of clopidogrel, both had loss of function mutation, one
being poor metabolizer (*2/*2) and other intermediate (*1/*2).
Analysis regarding this finding could not be made due to less
number of events. Loss of function allele was not associated
with any significant increase in acute coronary events in pa-
tients on clopidogrel.
Our results, which refute clinical significance of genetic
polymorphisms in CYP2C19 gene are supported by recent
studies. A Genetic substudy of CURE trial29 studied whether
the benefits of clopidogrel varies according to the CYP2C19
metabolizer status. The study population consisted of pa-
tients with ACS, most of whomwere managed conservativelypulation and comparison with present study.
3 allele *4 allele *5 allele *17 allele
0.5% 0.09% NA 16%
0.03% 0.24% 0% 18%
0.4% 0.25% 0.017% 21%
2.4% 0% 0% NA
2.2% NA NA NA
0% NA NA 18%
1% NA NA 16.5%
0% 0% 0% 35.45%
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 1 6e2 4 23with only 18% receiving percutaneous coronary in-
terventions. The metabolizer status of clopidogrel didn’t in-
fluence any of the primary or secondary efficacy outcomes in
this study. A recent meta-analyses involving more than
25,000 patients (30% carrying reduced-function allele) from
genetic substudy of TRITON-TIMI 38, CURE, PLATO,
CHARISMA, and ACTIVE-A studies also echoed similar
trends.30 The meta-analyses found that patients with a loss
of function allele, did not have increased risk of a cardio-
vascular events, HR ¼ 1.23 (95% CI 0.97e1.55), however they
were prone to increased risk of ST, HR ¼ 2.24 (95% CI
1.52e3.30). The authors concluded that effects of CYP2C19
reduced-function alleles on clopidogrel, when applied to all
users as a whole may not be clinically significant, however a
link to stent thrombosis remains.
Thus the role of CYP2C19 polymorphisms influencing
clinical outcomes differs according to the study group. When
applied to invasively managed population, these genetic
polymorphisms influence the clinical outcomes, however
their role in influencing clinical outcomes in patient popula-
tion managed conservatively is at the best modest.
All the clinical studies of CYP2C19 polymorphisms over-
whelmingly represented the Caucasian population. Though
there are studies in Indian population showing attenuated
platelet inhibition to clopidogrel in poor metabolizers27,31; no
study has evaluated clinical significance of this entity. Our
study is the first study in the Indian population to study
clinical significance of CYP2C19 reduced-function allele.
Findings of this study, which had many (50.5%) patients with
stable coronary artery disease supports the notion that role
of CYP2C19 polymorphisms in dictating clinical outcome in
patients of coronary artery disease is undermined when
applied to conservatively managed patients or the entire
population of clopidogrel users as a whole. P2Y12 receptor
gene polymorphisms are also associated with clopidogrel
resistance.32,33 Platelet activity testing could have taken this
factor into account. However we did not conduct platelet
activity testing in our study population, hence co-existence of
these polymorphisms could have influenced the results. May
be a similar study involving only high risk patients and those
receiving PCI, together with platelet activity testing show a
positive association of genetic polymorphisms in CYP2C19
gene and clinical outcomes.6. Limitations
Considering the high prevalence of genetic polymorphisms in
the population, this relatively small number of patients in the
study limits statistical inferences. This was a point study and
follow-up of patients with loss of function mutation for cor-
onary events has not been done. Clopidogrel CYP2C19 poly-
morphisms have a clinical implication in setting of PCI or
high-risk patients with USA/NSTEMI/STEMI; however our
study population included a large number of stable coronary
artery disease patients, which might have diluted the clinical
effect of these polymorphisms. Moreover, we did not conduct
platelet activity testing in our study population; hence co-
existence of other factors influencing clopidogrel induced
platelet inhibition such as P2Y12 gene polymorphisms couldhave influenced the results. However, this is the first study of
CYP2C19 gene polymorphisms and its clinical implication in
Indian patients.7. Conclusions
Loss of function CYP2C19*2 and gain of function CYP2C19*17
polymorphisms in Indian population are very common as
compared to other populations. Other loss of function alleles
*3, *4 and *5 were not found, and even if present form a very
small group. Loss of function status does not affect the clinical
outcomes. A larger study involving high risk patients with PCI,
together with, platelet activity testing, which would also take
into account effect of P2Y12 receptor polymorphisms, may be
required to establish the role of CYP2C19 gene polymorphisms
in clinical practice.Conflicts of interest
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